Highlights

For maintaining a remission though, an anti-interleukin may be even better, and the best drug right now, although it’s not yet approved, I think in Crohn’s, might actually be an S1P, because consider the mechanism of action, it keeps the lymphocytes locked up in their barracks.

I believe that in the coming years, we are going to see the biologics largely replaced in their market share by the small molecules, the small fusion receptor proteins, or the JAKs. I’m pretty hot on the JAK inhibitors for their rapid action, and even some of the new drugs like vidofludimus.

We’re going to see these things within class, but I think the bigger changes in a saturated market, as you put it, are going to come with competition among classes, the S1Ps, or the JAKs, maybe the enzyme inhibitors in time over the immune drugs, maybe the miRNA drugs over all the others.